Novo receives a positive CHMP opinion for once-weekly Sogroya® (somapacitan) to treat children with idiopathic short stature in Europe.
Novo has secured a positive CHMP opinion for FREHEMGO® (denecimig) to treat haemophilia A in adults and children, offering the first FVIIIa mimetic with once-monthly, bi-weekly, and weekly dosing options in a pre-filled pen.
Three major drugmakers disclosed missed primary endpoints within days of each other in September 2026 — here’s what went wrong, who it affects, and what it signals about pharma R&D.
Charles River Laboratories launches its NGS-enabled rapid cell banking platform, cutting production timelines by 40% through automated rapid microbiological testing and in vitro characterization.
Gilead Sciences accelerates global access planning for investigational once-yearly lenacapavir, expanding royalty-free generic licensing across 120 high-incidence countries alongside Phase 3 PURPOSE 365 trials.
Novo and Anthropic announced a September 16, 2026 collaboration pairing Claude Science with Novo’s R&D teams to tackle drug discovery challenges and strengthen AI-driven software engineering, with financial terms undisclosed.
The FDA has approved a label update cutting Amgen IMDELLTRA monitoring time for the first two doses from 22-24 hours to 6-8 hours, a change aimed at easing treatment burden for ES-SCLC patients in community oncology settings.
The Novo Nordisk rebrand introduces the single ‘Novo’ brand name, a ‘Lasting Health Starts Now’ platform, and a new culture framework called The Novo Way, unveiled by CEO Mike Doustdar ahead of the company’s 21 September Capital Markets Day in London.
Final PAPILLON trial results show Johnson & Johnson’s RYBREVANT (amivantamab-vmjw) plus chemotherapy achieved a 34.3-month median overall survival in EGFR exon 20 insertion-positive NSCLC — the longest reported to date in this historically hard-to-treat population.
Results from the AstraZeneca Enhertu DESTINY-Lung04 Trial show a 37% reduction in risk of disease progression or death, establishing first-line efficacy for T-DXd in HER2-mutant non-small cell lung cancer.
